fbpx
A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

Start earning CE Units in minutes!


Course Library New User Existing User Help

Diabetes in Dental Practice

Dental team members must demonstrate an understanding of glycemic monitoring and management to best serve patients with this common chronic disease.

0
Dental team members must demonstrate an understanding of glycemic monitoring and management to best serve patients with this common chronic disease

PURCHASE COURSE
This course was published in the January 2016 issue and expires 01/31/19.

The authors have no commercial conflicts of interest to disclose.

This 2 credit hour self-study activity is electronically mediated.

OBJECTIVES

After reading this course, the participant should be able to:

  1. Identify the two main types of diabetes.
  2. Discuss the value of laboratory testing and patient self-glucose monitoring.
  3. Explain how the HbA1c test can be used by oral health professionals to manage patients with diabetes.

Diabetes mellitus is a chronic disease affecting more than 29 million Americans, or approximately 9% of the U.S. population.1,2 About one-third of those with the disease remain undiagnosed, which means they are not adequately maintaining their health. With such a high prevalence, dentists and their teams will likely encounter patients with diabetes in clinical practice.

In order to understand diabetes, the dental team must learn how carbohydrates are metabolized (Figure 1).3,4 In a healthy individual, eating initiates a series of events that results in the breakdown of complex carbohydrates into simple sugars (glucose), which are then absorbed across the gastrointestinal lining into the bloodstream. As the blood glucose levels rise, insulin is secreted from the pancreatic β-cells. Glucose is too large a molecule to pass across the cell membrane of target cells — such as muscle cells, which are major consumers of glucose — without the action of insulin. Insulin binds to receptors on target cells, increasing permeability to glucose and allowing glucose to enter the target cells (Figure 2). Blood glucose levels decrease as glucose is absorbed into muscle cells.

There are two main types of diabetes: type 1 (formerly referred to as insulin-dependent diabetes), and type 2 (formerly referred to as noninsulin-dependent diabetes).4,5 Patients with type 1 diabetes lack the ability to produce insulin. Insulin production diminishes and eventually ceases when a patient’s autoimmune system destroys the pancreatic β-cells. These individuals rely on insulin injections to maintain normal blood glucose levels. Patients with type 1 diabetes are generally diagnosed in childhood or young adulthood.

Type 2 constitutes 90% to 95% of all diabetes cases and is more common in nonwhite populations. Its main cause is insulin resistance.3–5 Patients with type 2 diabetes can produce insulin, but their muscle cells exhibit insulin resistance. After a meal, the pancreas secretes insulin, but the insulin does not effectively activate its receptor on target cells, so glucose transport into the cells is inhibited. These patients do not rely on insulin injections for survival, but they may take medications that alter insulin production by the pancreas and insulin sensitivity at the target cells.6 Individuals with type 2 diabetes may also take supplementary insulin as part of a management regimen. Insulin resistance may be reduced by weight loss and pharmacotherapy, but is generally never restored to normal.

FIGURE 1. Carbohydrates are broken down into glucose molecules that are absorbed from the gut into the bloodstream. Increased blood glucose levels stimulate insulin secretion from the β-cells of the pancreas. This allows entry of glucose into target cells, where it is used for energy. Without insulin, glucose cannot enter most cells. As glucose moves into the tissues, blood glucose levels decrease, causing reduced insulin secretion until the next meal.
FIGURE 1. Carbohydrates are broken down into glucose molecules that are absorbed from the gut into the bloodstream. Increased blood glucose levels stimulate insulin secretion from the β-cells of the pancreas. This allows entry of glucose into target cells, where it is used for energy. Without insulin, glucose cannot enter most cells. As glucose moves into the tissues, blood glucose levels decrease, causing reduced insulin secretion until the next meal.

Diabetes and periodontal disease are closely associated via a two-way relationship in which poor glycemic control affects the periodontium and periodontal disease is associated with negative effects on glycemic control.2,7 Diabetes is a risk factor for periodontitis, even among young people.8,9 Current research also indicates that periodontitis may be an important factor in glycemic control.2 As such, it is imperative that patients with diabetes maintain their oral health and glycemic control. Communication and cooperation between medical and dental health care providers are critical to supporting the health of patients with diabetes.

†Taken two hours after glucose loading with 75 g of anhydrous glucose in water
*Fasting for >8 hours
†Taken two hours after glucose loading with 75 g of anhydrous glucose in water

LABORATORY TESTING AND SELF-GLUCOSE MANAGEMENT

Diabetes is diagnosed by a physician using various types of blood glucose testing (Table 1).5,10 Fasting blood glucose, casual blood glucose and post-prandial plasma glucose tests are used to evaluate blood glucose levels at a single point in time. These tests can evaluate only the blood glucose level at the moment the blood is drawn. In the bloodstream, glucose binds to numerous proteins, and, the higher the blood glucose levels, the higher the percentage of total protein that becomes glycated. As glucose circulates in the bloodstream, it attaches irreversibly to part of the oxygen-carrying hemoglobin molecule on red blood cells.

0116-diabetes-5The irreversible binding of glucose to hemoglobin is the basis of the HbA1c test. Glucose remains bound to the hemoglobin molecule for the entire lifespan of the red blood cell, which is approximately 120 days.11 High HbA1c levels indicate that a greater percentage of the hemoglobin on red blood cells has become glycated by the circulating blood glucose. Unlike the fasting, casual and post-prandial glucose tests that measure the glucose content of blood at any given moment, the HbA1c test provides the approximate glucose level in the bloodstream over the two-month to three-month period prior to the lab test.11

The HbA1c lab test can be used in both the diagnosis of diabetes and evaluation of long-term glycemic control.5 When used for diagnosis, an HbA1c value of less than 5.7% is considered normal. An HbA1c of ≥6.5% is diagnostic for diabetes, while an HbA1c between 5.7% and 6.4% is used to diagnose prediabetes.5

For patients diagnosed with diabetes, the quality of glycemic control is directly related to the risk of developing complications, such as kidney, eye and nerve disease.12,13 Therefore, physicians use diet, exercise and medications to maintain glycemic control in patients that is as close to normal as possible. The American Diabetes Association recommends that individuals with diabetes control their blood sugar so the HbA1c level remains <7%.5 In the U.S. diabetes population, only about 30% of patients are able to attain this target range.14 When a patient’s HbA1c rises above 8%, the association recommends the physician intervene with changes in the diabetes management regimen.5

0116-diabetes-6Just as a physician does not use a patient’s single blood pressure reading to evaluate hypertension, a single blood glucose reading from a fasting blood glucose or casual blood glucose test is not a good indicator of glycemic control. These tests are still useful, however, as they are both utilized to diagnose diabetes. In addition, individuals with diabetes use handheld glucometers to test their blood glucose multiple times per day. The single point-in-time glucometer readings let the patient instantly know his or her blood glucose level at the time the test was performed. Among individuals without diabetes, blood glucose levels rise and fall throughout the day as food is eaten and metabolized. In those with diabetes, this fluctuation in blood glucose levels is usually much wider. It is the patient’s responsibility to use the glucometer readings to maintain control of blood glucose levels, minimize highs and lows, and avoid hypoglycemia.

While the HbA1c test averages the glucose over the preceding two-month to three-month period, it does not provide an indication of the heights and depths of the peaks and valleys in normal daily blood glucose levels.5,6 In recent years, physicians have altered the way they discuss patients’ glycemic control. Individuals with diabetes use glucometers daily, and the units of measure for glucometers in the U.S. are milligrams per deciliter (mg/dL). Thus, patients become familiar with blood glucose readings such as 98 mg/dL and 156 mg/dL. The HbA1c test results are stated as a percentage, which maybe confusing for patients. As such, physicians now convert the results of the HbA1c test into an estimated average glucose or eAG (Table 2).5,15 The eAG simply converts the HbA1c percentages into mg/dL, making it easier for patients to interpret the results.

MANAGING DIABETES IN THE DENTAL OFFICE

Hypoglycemia is the most common complication of diabetes, particularly among those whose treatment involves insulin therapy.5 Shakiness, sweating and tachycardia often precede hypoglycemic reactions, but some events occur without warning. Table 3 provides a list of signs and symptoms.

FIGURE 2. This is a three-dimensional model of an insulin molecule. A hormone generated by the pancreas, insulin enables the body to use the glucose provided by the carbohydrates consumed through food and drink.
FIGURE 2. This is a three-dimensional model of an insulin molecule. A hormone generated by the pancreas, insulin enables the body to use the glucose provided by the carbohydrates consumed through food and drink.

Risk of hypoglycemia is highest among patients with well-controlled blood glucose levels and low HbA1c because they have lower average daily blood glucose levels.16 Symptoms of hypoglycemia generally present when a patient’s blood glucose levels drop below 60 mg/dL to 70 mg/dL, but can also occur at higher levels. Before receiving dental treatment, patients with diabetes should have their medication lists screened for drugs that can increase the risk of hypoglycemia.4,16 Oral health professionals should also inquire as to how often patients experience hypoglycemia and if there have been occurrences of hypoglycemia unawareness. This phenomenon occurs when a patient is asymptomatic for hypoglycemia and suddenly experiences an extreme reaction, such as seizure or loss of consciousness.4,17

The easiest way to prevent a hypoglycemic event in the dental office is to ask patients with diabetes to bring their glucometers to each dental appointment.16 Prior to the start of treatment, patients should check their blood glucose levels and clinicians should record the results in the treatment notes. Patients should also be asked if they have taken their diabetes medication, and when and how much they’ve recently eaten. By making this pretreatment blood glucose evaluation an office policy, the dental team communicates the importance of responsibly managing patients’ diabetes while under the team’s care.16 By asking patients to bring their glucometers to the dental office, clinicians are able to take an immediate assessment of blood glucose levels should the patient begin to ex­hibit signs or symptoms of hypoglycemia.

If the pretreatment glucometer reading approaches dangerously low levels, patients should consume approximately 15 grams of carbohydrates, such as 4 ounces to 6 ounces of juice, to raise the glucose to a safe range for the duration of the appointment. For example, if the pretreatment glucometer reading is 82 mg/dL before an hour-long procedure, the patient is close to the 60 mg/dL to 70 mg/dL level, the point at which hypoglycemia symptoms may occur. Therefore, it may be wise to give the patient approximately 15 grams of carbohydrates before proceeding. This amount usually raises blood glucose levels by 40 mg/dL to 60 mg/dL in a few minutes.

While the glucometer is an important short-term tool for assessing glucose levels, when determining how well an individual’s blood glucose is controlled over the long term, clinicians should request HbA1c values from the patient’s physician.4,16 Obtaining the HbA1c values from physicians, rather than patients, is important because patients may not always know their most recent percentages. In other cases, patients may guess inaccurately or generalize the results.

Obtaining HbA1c values from the past two years to three years paints a more accurate picture of patients’ true glycemic control over time. Some individuals with diabetes have HbA1c values that are stable over many years, while others have widely fluctuating values. Because the HbA1c provides an estimate of the average glucose levels, it offers insight into a patient’s risk of hypoglycemia. In general, the lower the HbA1c value, the higher the risk of hypoglycemia.16,18 For example, an individual with an HbA1c level of 10.5% has an estimated average glucose of about 255 mg/dL. This patient’s average glucose levels are far higher than the level at which hypoglycemia occurs. While hypoglycemia can affect those with high average glucose levels, if the short-term glucose drops precipitously, hypoglycemia is less likely for this patient than one whose HbA1c is 6%, which equates to an estimated average glucose of 126 mg/dL.

CONCLUSION

Dental professionals frequently treat patients with diabetes, and thus need to understand the basics of diabetes management. The HbA1c test is a critical component of assessing the quality of patients’ glycemic control over the long-term. In combination with point-in-time glucometer testing, the HbA1c also provides an assessment of risk for hypoglycemic emergencies in the dental office.

References

  1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta: US Department of Health and Human Services; 2014.
  2. Mealey BL, Oates TWI. Diabetes mellitus and periodontal diseases. J Periodontum. 2006;77:1289–1303.
  3. Mealey BL, O’Campo GL. Diabetes mellitus and periodontal disease. Periodontol 2000. 2007;44:127–153.
  4. Mealey BL. Management of the patient with diabetes mellitus in the dental office. In: Lamster IB, ed. Diabetes Mellitus and Oral Health: An Interpro­fessional Approach. Ames, Iowa: Wiley Blackwell Inc; 2014:99–120.
  5. American Diabetes Association. Standards of Medical Care in Diabetes — 2015. Diabetes Care. 2015;38(Suppl1):S8–S11.
  6. Kaur H, Weinstock RS. Glycemic treatment of diabetes mellitus. In: Lamster IB, ed. Diabetes Mellitus and Oral Health: An Interprofessional Approach. Ames, Iowa: Wiley Blackwell Inc; 2014:69–95.
  7. Mealey BL. Periodontal disease and diabetes: A two-way street. J Am Dent Assoc. 2006;137(Suppl10):26S–31S.
  8. Lalla E, Cheng B, Lal S, et al. Diabetes-related parameters and periodontal conditions in children. J Clin Periodontol. 2007;42:345–349.
  9. Taylor GW, Burt BA, Becker MP, et al. Non-insulin dependent diabetes mellitus and alveolar bone loss progression over 2 years. J Periodontol. 1998;69:76–83.
  10. Curtis JM, Knowler WC. Classification, epidemiology, diagnosis and risk factors of diabetes. In: Lamster IB, ed. Diabetes Mellitus and Oral Health: An Interprofessional Approach. Ames, Iowa: Wiley Blackwell Inc; 2014:27–44.
  11. Virtue MA, Furne JK, Nuttall FQ, Levitt MD. Relationship between GHb concentration and erythrocyte survival determined from breath carbon monoxide concentration. Diabetes Care. 2004;27:931–935.
  12. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
  13. U.K. Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
  14. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17–20.
  15. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1c assay into estimated average glucose values. Diabetes Care. 2008;31:1473–1478.
  16. Mealey BL. Managing patients with diabetes: First, do no harm. J Periodontol. 2007;78:2072–2076.
  17. Bakatselos SO. Hypoglycemia unawareness. Diabetes Res Clin Pract. 2011;93(Suppl1):S92–S96.
  18. Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997;46:271–286.
Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy